<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047732</url>
  </required_header>
  <id_info>
    <org_study_id>KB105-001</org_study_id>
    <nct_id>NCT04047732</nct_id>
  </id_info>
  <brief_title>Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)</brief_title>
  <official_title>A Phase I/II Clinical Trial of Topical KB105, a Replication-incompetent, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krystal Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krystal Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an intra-patient comparison of KB105 and placebo-administered Target Areas. The
      primary objectives of this study are to evaluate safety and Investigator Global Assessment
      (IGA) scale improvement of topically administered KB105.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to six adult subjects are planned for the Phase I portion of this study. Subjects are
      enrolled upon obtaining consent and meeting entry criteria. This study is an intra-patient
      comparison of KB105 and placebo-administered Target Areas. Patients will be evaluated for
      safety, and Target Areas will be assessed individually with the IGA and VIIS scales. Target
      Areas will be imaged and evaluated for safety and efficacy. Subjects will be on-trial for
      approximately 3.5 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Incidence of treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA) of disease severity</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Improvement of disease severity in the treatment area assessment through Investigator's Global Assessment (IGA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Index for Ichthyosis Severity (VIIS) scale, lamellar (L) standard</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Improvement of disease severity in the treatment area through use of the Visual Index for Ichthyosis Severity scale, lamellar (VIIS-L) standard assessment. The VIIS-L is a 4-point visual scale with 1 representing normal skin and 5 representing severe ichthyosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunofluorescence microscopy</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Level of transglutaminase 1 in KB105-administered skin as measured by immunofluorescence microscopy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>TGM-1 Related Autosomal Recessive Congenital Ichthyosis</condition>
  <arm_group>
    <arm_group_label>Topical KB105</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV1-TGM1 vector (KB105)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KB105</intervention_name>
    <description>KB105, a replication-incompetent, non-integrating HSV-1 vector expressing human transglutaminase 1 (TGM1) formulated as a topical gel</description>
    <arm_group_label>Topical KB105</arm_group_label>
    <other_name>HSV1-TGM1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetic diagnosis of TGM1-deficient ARCI with a null TGM-1 mutation;

          -  Clinical diagnosis of lamellar ichthyosis;

          -  Age: 18 years old or older;

          -  Individual site IGA score of 3 to 4 at the target areas

        Exclusion Criteria:

          -  Medical instability limiting ability to travel to the investigative center;

          -  Medical illness expected to complicate participation, such as an active infection
             with: HIV, hepatitis B (as determined by hepatitis B surface antigen screening),
             hepatitis C (as determined by detection of hepatitis C antibodies or a positive result
             of hepatitis C);

          -  Patient has a physical condition or other dermatological disorder (e.g., atopic,
             seborrheic, or contact dermatitis, psoriasis, tinea infections, etc.) which, in the
             Investigator's opinion, might impair evaluation of the Target Areas or which exposes
             the patient to unacceptable risk by study participation;

          -  Pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lawrence C Parish, M.D.</last_name>
    <phone>(215) 563-7330</phone>
    <email>larryderm@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hirak B Routh, MDDS</last_name>
    <phone>(215) 563-7330</phone>
    <email>hirakbrouth@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Paddington Testing Company, Inc.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirak Routh</last_name>
      <phone>215-563-7330</phone>
      <email>hirakbrouth@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Parish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ichthyosis</mesh_term>
    <mesh_term>Ichthyosis, Lamellar</mesh_term>
    <mesh_term>Ichthyosiform Erythroderma, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

